SYNAIRGEN PLC
Develops inhaled antiviral therapies for severe respiratory diseases.
SNG | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0381Z20
- LEI:
- 213800IMMTOPPDF8HD24
- Country:
- United Kingdom
- Address:
- MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON
- Website:
- https://www.synairgen.com/
- Sector:
- Manufacturing
Description
Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-06 08:00 |
Synairgen Presents SNG001 Data at ESWI
|
English | 13.1 KB | ||
| 2021-11-19 15:26 |
Holding(s) in Company
|
English | 49.5 KB | ||
| 2021-11-11 08:00 |
Synairgen completes Phase III recruitment
|
English | 17.5 KB | ||
| 2021-11-08 13:58 |
Holding(s) in Company
|
English | 52.4 KB | ||
| 2021-10-26 16:13 |
Holding(s) in Company
|
English | 50.5 KB | ||
| 2021-10-21 18:39 |
Holdings in Company
|
English | 49.6 KB | ||
| 2021-10-21 08:00 |
Grant of Options
|
English | 29.2 KB | ||
| 2021-10-20 08:00 |
SNG001 progresses to Phase 3 of ACTIV-2 trial
|
English | 13.1 KB | ||
| 2021-10-13 08:00 |
Synairgen appoints Gareth Walters, Ph.D. as CRO
|
English | 12.1 KB | ||
| 2021-10-05 12:25 |
Holding(s) in Company
|
English | 48.6 KB | ||
| 2021-09-30 08:02 |
Non-Executive Director Appointment
|
English | 14.5 KB | ||
| 2021-09-30 08:00 |
Interim results
|
English | 147.0 KB | ||
| 2021-09-21 08:00 |
Synairgen Notice of Interim Results
|
English | 11.0 KB | ||
| 2021-09-10 12:30 |
Holding(s) in Company
|
English | 49.6 KB | ||
| 2021-08-12 17:12 |
Exercise of Options and Total Voting Rights
|
English | 53.7 KB |
Automate Your Workflow. Get a real-time feed of all SYNAIRGEN PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SYNAIRGEN PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SYNAIRGEN PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
